Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2017-06-12 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is very short (1800 characters) and explicitly states: "Attached hereto is a report on *Kamada Receives Additional Milestone Payment Under GLASSIA� Exclusive Supply and Distribution Agreement with Shire*" followed by a filename (*FINAL_isa.pdf*). This structure indicates that the document itself is an announcement about the publication of another report, rather than the full report content. It is filed under 'Immediate Report' regulations with the Israel Securities Authority and Tel Aviv Stock Exchange. Since it is an announcement of a report's availability and does not fit specific categories like DIV, ER, or 10-K, it falls under the category for announcing the release of company reports, which is Report Publication Announcement (RPA).
2017-06-12 English
Immediate Report
Investor Presentation Classification · 1% confidence The document is a press release dated June 7, 2017, announcing a strategic update regarding the clinical development program for Alpha-1 Antitrypsin (G1-AAT IV) for Graft-Versus-Host Disease (GvHD). It details the transfer of an IND application from Shire to Kamada and discusses future clinical plans, market opportunity, and existing agreements. This type of announcement, focusing on clinical trial updates, regulatory milestones (IND transfer, FDA/EMA feedback), and strategic business decisions, is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the specific financial reporting codes (10-K, ER, IR). Since it is a detailed update intended for investors about pipeline progress and strategy, Investor Presentation (IP) is the most appropriate fit among the provided options, as it often contains more narrative and strategic detail than a simple Earnings Release (ER) or a generic Regulatory Filing (RNS). It is not a transcript (CT), a formal financial report (10-K, IR), or a management discussion (MDA), but rather a strategic update presentation style in text format.
2017-06-07 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states: 'Attached hereto is a report on *Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease* *FINAL_isa.pdf*'. Since the document itself is short (1796 chars) and serves primarily to announce the publication of an attached or linked report, it fits the definition of a Report Publication Announcement (RPA). It is not the full report (like ER, IR, or 10-K), but the announcement of its release.
2017-06-07 English
Other Report or Announcement
Board/Management Information Classification · 1% confidence The document is a press release dated June 5, 2017, announcing the appointment of a new executive, Michal Stein, M.D., as Vice President and Medical Director. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2017-06-05 English
Other Report or Announcement
Board/Management Information Classification · 1% confidence The document is very short (1820 characters) and explicitly states, "Attached hereto is a report on *Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director*" followed by a filename. This structure indicates that the document itself is an announcement about the publication of another report or filing, rather than the full content of a major financial report (like 10-K or IR). The content concerns a change in senior management (appointment of a VP/Medical Director). According to the definitions, announcements regarding changes in senior management fall under 'Board/Management Information' (MANG). However, given the 'MENU VS MEAL' rule, since this is an announcement stating a report is attached/published, it strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the subject matter is specific (management change), and it's an announcement of a document, RPA is a strong candidate if the announcement itself is the primary focus, but MANG describes the *content* of the attached document. Given the context of regulatory filings, an announcement of a management change is often filed as a specific report type. Since the text explicitly announces the appointment of a VP, MANG is the most accurate content classification, but the format suggests RPA. I will prioritize the content type (Management Appointment) over the announcement format, as MANG is a specific category, whereas RPA is often a fallback for short announcements. However, the presence of the ISA/TASE headers and the structure strongly suggest this is a regulatory filing announcing the event. Let's re-evaluate: The content is a management change (MANG). The format is an announcement of an attached document (RPA/RNS). Since MANG is a specific content category, and this is the official notification of that event, MANG is the best fit for the *subject matter* being reported. If the document was just the PDF itself, it would be MANG. As it is the announcement *of* the PDF, RPA or RNS might apply. Given the specific nature of the content (management appointment), MANG is the most descriptive category for the underlying event being disclosed.
2017-06-05 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a press release from Kamada Ltd. dated May 24, 2017, announcing that updated data from their Phase 2 clinical trial of inhaled Alpha-1-Antitrypsin (AAT) was presented at the 2017 American Thoracic Society (ATS) International Conference. It details clinical results, quotes executives and the primary investigator, and discusses future regulatory steps (FDA/EMA submissions). This format—a news announcement summarizing recent developments, clinical data presentation, and business outlook—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical updates. Since it focuses on clinical trial results and regulatory milestones rather than comprehensive financial performance for a period (which would suggest IR or 10-K), and it is not a transcript (CT) or a formal presentation (IP), the best fit among the provided options for a press release announcing key operational/clinical progress is the Earnings Release (ER) category, as these often contain operational highlights alongside any financial context, or it could be classified as a general Regulatory Filing (RNS) if ER is too focused on financials. Given the strong focus on clinical data presentation and future regulatory strategy, it functions as a major corporate update. However, ER is typically for quarterly/periodical financial results. Since this is a clinical data update announcement, and it is not a formal report itself, it fits best as a general announcement. If we must choose between ER and RNS, RNS is the broader regulatory announcement category. Let's re-evaluate: It is a press release announcing clinical data presentation. This is a common type of announcement that often accompanies or precedes a formal financial filing, but it is not the financial filing itself. It is not a Call Transcript (CT), Investor Presentation (IP), or Interim Report (IR). It is most closely aligned with an Earnings Release (ER) if it contains any financial context, or RNS if it is purely operational/clinical news. Since it is a press release announcing clinical progress, and not a formal financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for non-standard, yet important, corporate news that doesn't fit the specific report types.
2017-05-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.